Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes
Status:
Completed
Trial end date:
2003-04-24
Target enrollment:
Participant gender:
Summary
This this trial is conducted in Europe. The aim of this trial is to compare glycaemic control
of biphasic insulin aspart 30 (BIAsp 30) alone or combined with insulin aspart(IAsp) in
patients previously treated with conventional Biphasic Human Insulin 30/70.